HUDDINGE, Sweden and GLOSTRUP, Denmark, Sept. 2 /PRNewswire/ -- LightUp Technologies AB and DakoCytomation A/S today announced the market introduction of ReSSQ(TM) EBV Assay, a nucleic acid test (NAT) for detection and quantification of Epstein-Barr virus. The assay provides a rapid and accurate means of monitoring viral load of EBV in clinical specimens. Currently, it is validated for use in conjunction with the LightCycler(R) and ABI PRISM(R) 7000 SDS real-time PCR instrument platforms.
Ulrica Sehlstedt, Ph.D., Chief Executive Officer, commented, "The ReSSQ EBV Assay represents the most recent addition to our developing portfolio of products for infectious disease diagnostics. It follows our strategy to provide clinical laboratories with robust and cost effective diagnostic kits. As one component in the prevention of disease and management of infections, we are proud of being able to provide the healthcare community with an efficient and easy to use tool to monitor viral load before, during and after treatment of patients with EBV."
In June, LightUp Technologies and DakoCytomation announced a European distribution agreement. Under the agreement, ReSSQ EBV Assay will be marketed and sold by DakoCytomation in Europe. Eventually, the assay will be made available throughout the world.
Geoff Gower, Director of Microbiology at DakoCytomation, said, "We are happy to make this product available to clinicians and clinical laboratories involved in the management of immunocompromised patients. EBV infection is, for example, a major risk factor for developing lymphoproliferative disease (PTLD), a life-threatening complication of organ transplantation."
To meet company representatives and learn more about the ReSSQ Assays and the LightUp(R) Probe diagnostic platform technology, stop by the LightUp Technologies and DakoCytomation Booth No. 10 at the ESCV EuroVirology 2004 meeting on September 5-8 in Madrid.
About LightUp Technologies AB
LightUp Technologies AB is a company developing and commercialising innovative technologies for the fast-growing molecular diagnostic segment of the in vitro diagnostics (IVD) industry. Our first product range, the ReSSQ Assays, enables simpler and more accurate identification and quantification of disease-generating organisms. The unique LightUp Probe at the heart of the method is designed to work with real-time PCR and can be used in many medical applications, including gene mapping and disease diagnostics. LightUp Technologies was founded in 1998 and is located in Huddinge, south of Stockholm, Sweden. For more information, visit our web site at http://www.lightup.se/
About DakoCytomation A/S
DakoCytomation A/S, headquartered in Copenhagen, Denmark, is a leading cancer diagnostics company with a focus on personalized medicine. DakoCytomation offers systems solutions for clinical laboratories and life science researchers, providing tests and instruments so that physicians can link diagnostic results to specific therapies and optimize patient care. The privately held company has significant R&D and manufacturing activities in Denmark, UK and USA, with operations in 20 countries, distributors in 50+ countries and more than 1,300 employees. http://www.dakocytomation.com/
For more information, contact:
Ulrica Sehlstedt, Ph.D. Chief Executive Officer
LightUp Technologies AB
Direct line: +46 8 556 40 661
Direct line: +45 44 85 93 31
Cellular phone: +45 40 63 95 93
LightUp Technologies AB
CONTACT: Ulrica Sehlstedt, Ph.D. Chief Executive Officer, of LightUpTechnologies AB, +46-8-556-40-661, email@example.com; or GitteSjorslev, Communications Manager of DakoCytomation A/S, +45-44-85-93-31, orcellular, +45-40-63-95-93, firstname.lastname@example.org